Keytruda Growth Gives Merck a Narrower Path Through Patent Risk

Last updated: November 3, 2026

Merck delivered a third-quarter beat, raised its adjusted profit outlook and reported stronger-than-expected Keytruda sales. The encouraging headline carries a caveat: the company remains heavily exposed to the loss of exclusivity facing Keytruda from 2028.

• Merck reported revenue of $18.09 billion, up 5% from a year earlier.
• Keytruda generated $8.60 billion in quarterly sales, including $830 million for Qlex.
• Adjusted earnings were $2.49 per share, and adjusted profit guidance increased.
• The 2026 revenue forecast retained its upper bound but moved upward at the lower end.
• Winrevair and Gardasil beat sales expectations, while animal health fell short.

Why this matters

The quarter’s most important signal was not simply that Merck exceeded estimates. It was the early commercial performance of Keytruda Qlex, an under-the-skin injection positioned as the successor to the original intravenous treatment.

Qlex recorded $830 million in sales, above the $649 million analysts expected and the highest quarterly total since its 2025 launch. That uptake matters because Merck faces generic competition after Keytruda’s key patents begin expiring in 2028. If patients and physicians embrace the newer format, Qlex could help defend market share and sustain sales beyond the original version’s loss of exclusivity.

This is strategic potential, not a guarantee. The important variables are continued adoption and the pace at which patients transition from intravenous Keytruda to Qlex. One strong launch quarter shows early demand, but it does not resolve the long-term patent challenge.

The broader portfolio offered useful support. Winrevair, a treatment for a rare, deadly lung condition, generated $694 million in sales, up 93% from a year earlier and above the $645 million expected. Gardasil generated about $2 billion on stronger U.S. Demand, surpassing the $1.76 billion analysts expected. Animal health sales were $1.68 billion, slightly below estimates.

The background behind the earnings

Keytruda is an immunotherapy drug and a central pillar of Merck’s business. Its $8.60 billion in quarterly sales exceeded the $7.73 billion analysts expected, giving Merck meaningful momentum heading toward the 2028 patent window.

The company has pursued acquisitions and licensing agreements while introducing Qlex. Its stated strategy is to make the newer injectable form a cornerstone of growth and move patients away from the original intravenous version.

That approach requires more than a strong initial sales comparison. It depends on whether Qlex can maintain momentum as more patients become eligible to switch and whether the transition protects the broader franchise rather than merely changing its delivery format.

The financial results also illustrate why the headline beat is incomplete. Merck reported net income of $5.07 billion, or $2.04 per share, compared with $5.79 billion, or $2.32 per share, a year earlier. Revenue grew, adjusted earnings were strong, and reported net income declined, sending different signals about the quarter.

Merck now expects adjusted earnings of $2.77 to $2.82 per share, up from $2.66 to $2.76. The revised range includes a one-time $400 million charge, or 12 cents per share, tied to its licensing agreement with Chinese cancer drugmaker SciBrunch. Its 2026 revenue guidance narrowed to $66.8 billion-$67.3 billion from $66.3 billion-$67.3 billion.

Our analysis: growth is real, but concentration remains

Merck has evidence of genuine growth. Keytruda beat expectations, Qlex is establishing a meaningful sales base, and Winrevair and Gardasil also exceeded sales forecasts. The result would be a mistake to dismiss as cosmetic.

The trade-off is concentration. Keytruda’s scale supports Merck now but also leaves the company vulnerable to patent, pricing and uptake decisions beyond its control. Qlex may narrow that vulnerability, but it does not eliminate it.

The 2028 patent window explains why Merck has been active in dealmaking and treating Qlex as a strategic asset. For investors, the decisive metric is not Qlex sales alone; it is whether the franchise remains durable as patients transition formats. For patients, convenience may be the immediate benefit. For Merck, the commercial benefit depends on conversion translating into durable demand.

There is also a broader lesson for professionals evaluating pharmaceutical companies or industries: current performance and long-term resilience are separate questions. A company can post excellent quarterly results while still needing a credible plan to reduce dependence on a dominant product.

A practical decision checklist for career decision-makers

Before joining a pharmaceutical company after a strong earnings report, evaluate the business beyond the latest revenue headline.

• Product concentration:** Determine how much of the company depends on its leading product and what would happen if that product weakened.
• Patent exposure:** Identify when important protections expire and how much time the company has to replace or extend revenue.
• Launch quality:** Look for sustained adoption, not only a first strong quarter or an analyst-beat comparison.
• Pipeline breadth:** Assess whether newer products are large enough to contribute meaningfully rather than merely post occasional growth.
• Capital allocation:** Review acquisitions, licensing agreements and other charges that may affect the apparent relationship between revenue, earnings and cash costs.

The same checklist can inform a one-page brief for a role in corporate strategy, commercial operations or business development. It turns an impressive earnings story into a more useful assessment of whether the company’s apparent growth is diversified, durable and aligned with the work a prospective employee would actually do.

What to watch next

The next meaningful test is whether Qlex sales continue rising as the product moves beyond its launch year. Continued growth, broader acceptance and the pace of patient conversion will matter more than a single forecast beat.

Investors and prospective employees should also track Merck’s 2026 revenue trajectory, contributions from Winrevair and Gardasil, and the treatment of future licensing charges. The central question is whether Merck can broaden its growth base quickly enough to reduce dependence on Keytruda before the 2028 patent window.

Key takeaways

• Qlex exceeded analyst expectations and reached $830 million in quarterly sales.
• Stronger adoption could help Merck protect Keytruda revenue as key patents begin expiring in 2028.
• Winrevair and Gardasil provided portfolio support, but product concentration remains the central risk.
• Career decisions should assess patent exposure and diversification rather than relying on one earnings beat.